2,5-octanediol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 2,5-octanediol
• 英文别名: 2,5-Octandiol；octane-2,5-diol
• 化学式: C₈H₁₈O₂
• 分子量: 146.23
• InChiKey: AZVKGHXATHHFRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,5-octanediol 在 chromium(VI) oxide 作用下， 以 溶剂黄146 为溶剂， 生成 octane-2,5-dione
  参考文献：
  名称：

  Thewalt,K.; Rudolph,W., Journal fur praktische Chemie (Leipzig 1954), 1964, vol. 26, p. 233 - 261

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(2-呋喃基)-3-丁烯-2-酮 在 Cu-chromit 氢气 作用下， 以 1,4-二氧六环 为溶剂， 230.0 ℃ 、30.4 MPa 条件下， 生成 2,5-octanediol
  参考文献：
  名称：

  Thewalt,K.; Rudolph,W., Journal fur praktische Chemie (Leipzig 1954), 1964, vol. 26, p. 233 - 261

  摘要：

  DOI：

文献信息

• INDAZOLE COMPOUNDS
  申请人：Nakano Seiji

  公开号：US20100160256A1

  公开（公告）日：2010-06-24

  Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have 133 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic agent for diabetes mellitus, obesity, hyperlipidemia, depression, diseases caused by gallstones or hypermotility of the biliary tract, diseases caused by hyperactivity of the digestive tract, interstitial cystitis, overactive bladder or urinary incontinence, or as therapeutic and prophylactic agents for diseases concomitant with decreased tears.

  提供的是以下公式（A-1）和公式（1）所代表的化合物，或其盐。公式（A-1）和公式（1）的化合物或其盐具有133肾上腺素受体激动剂活性，因此可作为治疗和预防糖尿病、肥胖、高脂血症、抑郁症、胆石症或胆道高动力性疾病、消化系统过度活动引起的疾病、间质性膀胱炎、膀胱过度活动或尿失禁的药物，或作为治疗和预防伴随眼泪减少的疾病的药物。
• Biocatalytic synthesis of non-vicinal aliphatic diols
  作者：Ana C. Ebrecht、Jasmin C. Aschenbrenner、Martha S. Smit、Diederik J. Opperman

  DOI：10.1039/d0ob02086a

  日期：——

  Biocatalysts are receiving increased attention in the field of selective oxyfunctionalization of C–H bonds, with cytochrome P450 monooxygenases (CYP450s), and the related peroxygenases, leading the field. Here we report on the substrate promiscuity of CYP505A30, previously characterized as a fatty acid hydroxylase. In addition to its regioselective oxyfunctionalization of saturated fatty acids (ω-1

  在细胞色素P450单加氧酶（CYP450s）和相关的过加氧酶的C–H键选择性加氧官能化领域，生物催化剂受到了越来越多的关注，并引领了该领域。在这里我们报告CYP505A30的底物滥交，以前被表征为脂肪酸羟化酶。除了饱和脂肪酸的区域选择性氧官能化（ω-1–ω-3羟基化）以外，伯脂肪醇也具有相似的区域选择性。此外，烷烃如正辛烷和正癸烷也容易被接受，从而允许通过顺序的氧合产生非邻位二醇。
• The preparation of trialkylvinylborates and their reactions with oxiranes and with iodine. A facile synthesis of 1,4-alkanediols and 1-alkenes
  作者：K. Utimoto、K. Uchida、M. Yamaya、H. Nozaki

  DOI：10.1016/0040-4020(77)80381-5

  日期：1977.1

  Reaction of trialkylboranes with vinyllithium gives non-isolable lithium trialkylvinylborates which react with oxirane and methyloxirane affording 1,4- and 2,5-alkanediols, respectively. Treatment of trialkylboranes with vinylmagnesium bromide produces bromomagnesium trialkylvinylborates which analogously afford alkanediols. Successive treatment of the borates with aqueous alkali and iodine provides

  三烷基硼烷与乙烯基锂的反应得到不可分离的三烷基乙烯基硼酸锂，其与环氧乙烷和甲基环氧乙烷反应，分别得到1，4-和2，5-链烷二醇。用乙烯基溴化镁处理三烷基硼烷可得到三烷基乙烯基硼酸溴镁，类似地得到链烷二醇。用碱金属和碘水溶液连续处理硼酸盐可得到1-烯烃。
• TETRAHYDROFURAN DERIVATIVES AND USE THEREOF AS PLASTICIZERS
  申请人：BASF SE

  公开号：US20160075671A1

  公开（公告）日：2016-03-17

  The invention relates to tetrahydrofuran derivatives of general formula (I), wherein X stands for *—(C═O)—O—, *—(CH2)n-O—, or *—(CH2)n-O—(C═O)—, wherein * represents the point of bonding to the tetrahydrofuran ring and n has the value 0, 1, or 2; and R1 and R2 are selected independently of each other from among C4-C5 alkyl and C5-C6 cycloalkyl, wherein the cycloalkyl groups are unsubstituted or can be substituted by at least one C1-C10 alkyl group, a plasticizer composition that contains said tetrahydrofuran derivatives, molding masses that contain a thermoplastic polymer or an elastomer and such a tetrahydrofuran derivative. The invention further relates to a method for producing said tetrahydrofuran derivatives, and to the use of said tetrahydrofuran derivatives

  该发明涉及一般式(I)的四氢呋喃衍生物，其中X代表*—(C═O)—O—、*—(CH2)n-O—或*—(CH2)n-O—(C═O)—，其中*代表与四氢呋喃环的连接点，n的值为0、1或2；R1和R2分别从C4-C5烷基和C5-C6环烷基中独立选择，其中环烷基可以是未取代的或可以被至少一个C1-C10烷基基团取代，含有所述四氢呋喃衍生物的增塑剂组合物，含有热塑性聚合物或弹性体以及该四氢呋喃衍生物的成型物料。该发明还涉及制备所述四氢呋喃衍生物的方法，以及使用所述四氢呋喃衍生物。
• [EN] PROCESS FOR THE PREPARATION OF CLARITHROMYCIN<br/>[FR] PROCEDE POUR PREPARER DE LA CLARITHROMYCINE
  申请人：SANDOZ AG

  公开号：WO2005090377A1

  公开（公告）日：2005-09-29

  The present invention relates to a process for the production of clarithromycin using solvents with a low toxic potential and water.

  本发明涉及一种利用具有低毒性潜力的溶剂和水生产克拉霉素的方法。